Patients Discontinuing Anti-Obesity Injections Regain Pounds Far More Rapidly Compared to People Using Diet and Exercise

New research suggests that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who stop traditional lifestyle regimens.

Published data in a prominent medical journal demonstrates that while obese people can lose a large proportion of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.

"People purchasing these treatments must be informed of the danger of rapid weight regain when the treatment is stopped," cautioned lead investigator Dr. Susan Jebb.

This pace of recovery means a return to starting weight within about one and a half years.

Comparing Approaches

The study, which reviewed 37 of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with conventional dieting.

The team emphasize that individuals who lose weight through diet and exercise typically have a more gradual creep back—around 0.1 kg a month—post-intervention.

Understanding the Fast Rebound

Doctors suggest the mechanism of the injections is key to understanding the heightened regain.

These medications mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.

"Long-term administration of GLP-1 levels far above than the body's typical production could lead to the system to produce less of its endogenous hormone, and could reduce responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.

"Stopping of this GLP-1 'fix' leads to appetite is no longer kept in check, making excessive eating a significant risk."

A Chronic Disease?

Health authorities advise the jabs for individuals with obesity-related medical conditions, alongside prescribed lifestyle changes.

A number of clinicians argue that, due to the likelihood of weight regain, the therapy should be considered life-long.

This perspective is echoed by drug manufacturers, who note that the results "highlight the long-term nature of obesity," akin to managing conditions like diabetes.

Patient Experiences

Individuals who have come off the medication report a intense resurgence of hunger.

"It felt as if a switch that goes on and I was suddenly extremely hungry," recalled a patient.

This difficulty is worsened if patients have not developed lasting dietary or behavioural modifications during therapy.

Significant Use

Recent estimates indicate that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest continuing to grow.

• Adoption is greater among females than males.
• The middle-aged age group shows the highest usage rates.
• A large proportion access the drugs through private prescriptions rather than public health services.

Finally, experts emphasize that while these medications are powerful tools for weight loss, they are not a permanent solution and long-term success relies on ongoing behavioural management.